DNM2 and breast carcinoma: In spite of the differences in cytokeratin expression pattern between luminal and basal-like breast cancers, luminal CK19 was chosen as the most suitable marker for identifying breast cancer metastases in lymph nodes by means of OSNA because virtually all (98.2 %) primary breast cancers were found to express this cytoskeletal protein [10].